PATENT CLAIM ANALYSIS

Application Number: 16388767
Application Type: Utility
Filing Date: 2019-04
Publication Date: 2019-08
Patent Classification: ["424", "093210"]

Abstract:
The present inventions provides systems and methods to manufacture genetically modified lymphocyte cells via the use of linear DNA expression amplicons, and uses of such genetically modified lymphocyte cells to treat disease. The present invention also provides for the composition of genetically modified lymphocyte cells.

Claim (Index 17):
The method of  claim 15 , wherein the linear DNA expression amplicon further comprises a centromere, telomere or origin or replication.

Metadata:
- Claim Count in Document: 29.0
- Percentile: 100.0
- Lexical Diversity: 1.54839
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15120060', '16361370', '15659792', '14403937', '14941295']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.567314788555123
- 35 USC 102 Novelty (BERT): 0.5083944289002713
- Combined Prediction Score: 0.5614227525896378
- Mean Citation Score: 223.817592
- Max Citation Score: 230.45454
- Similarity Product: 158.62881350031853

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test